Chromadex Corp reports results for the quarter ended December 31 - Earnings Summary

Niagen Bioscience

05/03/2025 01:51

Chromadex Corp CDXC.OQ reported quarterly adjusted earnings of 9 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported breakeven earnings per share.  The mean expectation of three analysts for the quarter was for earnings of 2 cents per share. Wall Street expected results to range from zero cents to 4 cents per share.

Revenue rose 37.4% to $29.13 million from a year ago; analysts expected $26.73 million.

Chromadex Corp's reported EPS for the quarter was 9 cents​.

The company reported quarterly net income of $7.18 million.

Chromadex Corp shares had risen by 3.7% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts was unchanged in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Chromadex Corp is $8.00

This summary was machine generated from LSEG data March 5 at 01:51 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
0.02
0.09
Beat
Sep. 30 2024
0.00
0.02
Beat
Jun. 30 2024
-0.02
0.00
Beat
Mar. 31 2024
-0.02
-0.01
Beat